Feed DSGN
DS

Design Therapeutics, Inc. DSGN · NASDAQ

$10.49 -2.24% (-$0.24)

Market cap
$656.5M
Enterprise value
$645.6M
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
-38.9%
Bruto marža
-
Neto marža
-
Dividend yield
-
Payout ratio
-
Neto dolg/EBITDA
-
Beta
1.69
Free float
55.3%

O podjetju

Design Therapeutics, Inc. is a biopharmaceutical company specializing in the development of drugs for genetic diseases and neurodegenerative disorders. Their main focus is on discovering and developing therapeutics aimed at correcting defective genetic mechanisms associated with these diseases. The company utilizes modern technologies such as RNA therapy, CRISPR-Cas9, and small molecule chemistry to identify and develop new drug molecules with the potential to modify the course of genetically inherited diseases. Design Therapeutics, Inc. aims to bring innovative therapeutic approaches to patients suffering from genetic and neurodegenerative diseases in order to improve their quality of life.

Sector

Healthcare

Industry

Biotechnology

CEO

Pratik Shah

Employees

55

Headquarters

Carlsbad

Vrednotenje

Je današnja cena primerna?

Rast in ocene

Ali podjetje raste in kaj sledi?

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

Finančno zdravje

Ali zmore svoj dolg?

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.